<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00123110</url>
  </required_header>
  <id_info>
    <org_study_id>AG0031</org_study_id>
    <secondary_id>K23AG019161</secondary_id>
    <secondary_id>K23AG1916101A1</secondary_id>
    <secondary_id>5P30DK019525</secondary_id>
    <nct_id>NCT00123110</nct_id>
  </id_info>
  <brief_title>Insulin Resistance and Testosterone in Women</brief_title>
  <official_title>Insulin Resistance and Testosterone in Non-Diabetic Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The John A. Hartford Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania Diabetes and Endocrinology Research Center (DERC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TAP Pharmaceutical Products Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if a relationship between insulin
      resistance (IR) and testosterone (T) exists in women who have already gone through menopause.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study tests the central hypothesis that insulin resistance (IR) increases androgen (male
      sex hormone) production in postmenopausal women. Participation will include five visits, each
      lasting on average 2.5 hours, over a period of 13-20 weeks.

      At the screening visit, the participant's medical history, current use of medications and
      dietary supplements, and social habits will be recorded. This information will be reviewed on
      each subsequent visit; participants are asked to maintain their current diet and physical
      activity level throughout the study.

      A brief physical exam will be performed, and blood will be drawn.

      At the 2nd (baseline) visit, patients will undergo a euglycemic-hyperinsulinemic clamp (a
      procedure to measure insulin sensitivity by continuous intravenous infusion of insulin, and
      variable infusion of glucose). Blood samples will be drawn throughout the procedure. At
      completion, the insulin infusion will be stopped, participants will be fed, and the glucose
      infusion continued for at least 15 minutes to ensure stability of the blood glucose
      concentration. After the procedure, participants will be randomized to receive either
      metformin plus leuprolide placebo, leuprolide plus metformin placebo, or metformin placebo
      plus leuprolide placebo. The leuprolide or leuprolide placebo will be administered as an
      injection by a nurse. The metformin or metformin placebo will be dispensed to the participant
      in the form of pills, with instructions for titrating the dose. Participants will be
      contacted by telephone once weekly during the titration period to assess drug tolerability
      and adverse events (AEs). Participants will be maintained at their maximum tolerated dose for
      the duration of the study intervention period.

      Participants will return every 4 weeks for follow-up. Blood will be drawn, the nurse will
      administer the leuprolide or leuprolide placebo injection, and metformin or metformin placebo
      will be dispensed. At the final visit (week 12), participants will undergo a brief physical
      exam, and will then undergo a final euglycemic-hyperinsulinemic clamp.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Free Testosterone (T)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Percent change in free T by equilibrium dialysis between baseline and 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Insulin Sensitivity</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Change in insulin sensitivity (mg/kg/min) calculated from hyperinsulinemic euglycemic clamp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Luteinizing Hormone (LH) From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Homeostasis Model Assessment Index of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Insulin resistance calculated from homeostasis model assessment of insulin resistance (HOMA-IR) equation: fasting insulin x fasting glucose / 405. Higher values indicate more insulin resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Low Density Lipoprotein (LDL)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Systolic Blood Pressure</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free T and IR in Women in Whom Metabolic Syndrome is Present vs. Absent</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dehydroepiandrosterone Sulfate (DHEA-S)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Postmenopause</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin pill plus placebo injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>leuprolide injection plus placebo pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pill plus placebo injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprolide injection</intervention_name>
    <description>3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Lupron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo pill</intervention_name>
    <description>matching pill twice a day for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo injection</intervention_name>
    <description>matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women aged 50-79 years with absence of menses for 12 months; for women
             50-54 years, Follicle stimulating hormone&gt;30 U/mL to confirm postmenopausal status

          -  At least one intact ovary

          -  Free testosterone and fasting insulin levels within required study parameters

          -  Willing to comply with all study-related procedures

          -  Capable of giving informed consent

        Exclusion Criteria:

          -  History of cancer requiring treatment within the past 5 years (exceptions may be made
             by investigator)

          -  Hospitalization for treatment of vascular disease in the past 6 months

          -  Uncontrolled hypertension

          -  Hospitalization for chronic obstructive pulmonary disease or asthma in the past 3
             months

          -  Use of continuous oxygen at home

          -  Surgery in the last 30 days

          -  Positive for HIV

          -  Abnormal blood tests (hemoglobin, fasting triglycerides, fasting glucose, creatinine,
             liver function)

          -  History of diabetes mellitus or use of any anti-hyperglycemic medication in the past 3
             months

          -  Disease associated with disordered glucose metabolism (Cushing's disease, acromegaly,
             pheochromocytoma not surgically cured, chronic pancreatitis)

          -  History of chronic renal insufficiency

          -  Intravenous (IV) contrast studies with iodinated materials planned for the 12 week
             intervention period that cannot be postponed according to the participant's primary
             care provider

          -  Acute or chronic metabolic acidosis

          -  History of liver disease

          -  Congestive heart failure

          -  History of androgen-secreting tumors

          -  Hormone replacement therapy or antiandrogen use in past 6 months

          -  Use of dehydroepiandosterone (DHEA) or other androgen-containing products in past 6
             months

          -  Corticosteroid use, other than topical, ophthalmic, intraarticular, and inhaled
             preparations, in past 3 months

          -  Undiagnosed current vaginal bleeding

          -  Excessive alcohol intake, either acute or chronic; current illicit substance abuse

          -  Participation in an investigational drug study within 6 weeks prior to screening visit

          -  Serious or unstable medical or psychological conditions that, in the opinion of the
             investigator, would compromise the patient's safety or successful participation in the
             study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne R. Cappola, MD, ScM</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania Clinical and Translational Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16;287(3):356-9.</citation>
    <PMID>11790215</PMID>
  </reference>
  <reference>
    <citation>Golden SH, Ding J, Szklo M, Schmidt MI, Duncan BB, Dobs A. Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women: the atherosclerosis risk in communities study. Am J Epidemiol. 2004 Sep 15;160(6):540-8.</citation>
    <PMID>15353414</PMID>
  </reference>
  <reference>
    <citation>Larsson H, Ahrén B. Androgen activity as a risk factor for impaired glucose tolerance in postmenopausal women. Diabetes Care. 1996 Dec;19(12):1399-403.</citation>
    <PMID>8941471</PMID>
  </reference>
  <reference>
    <citation>Oh JY, Barrett-Connor E, Wedick NM, Wingard DL; Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care. 2002 Jan;25(1):55-60.</citation>
    <PMID>11772901</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 19, 2005</study_first_submitted>
  <study_first_submitted_qc>July 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2005</study_first_posted>
  <results_first_submitted>January 16, 2013</results_first_submitted>
  <results_first_submitted_qc>May 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 23, 2019</results_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The participants were recruited beginning 8/11/05 and continued until the last patient was consented on 4/8/08.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>metformin plus leuprolide placebo (LP) injection</description>
        </group>
        <group group_id="P2">
          <title>Leuprolide</title>
          <description>leuprolide plus metformin placebo (MP) pill</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>MP placebo pill plus LP placebo injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>metformin plus leuprolide placebo (LP) injection</description>
        </group>
        <group group_id="B2">
          <title>Leuprolide</title>
          <description>leuprolide plus metformin placebo (MP) pill</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>MP placebo pill plus LP placebo injection</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="4"/>
                    <measurement group_id="B2" value="58" spread="7"/>
                    <measurement group_id="B3" value="62" spread="7"/>
                    <measurement group_id="B4" value="58" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Free Testosterone (T)</title>
        <description>Percent change in free T by equilibrium dialysis between baseline and 12 weeks</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Randomized to metformin plus leuprolide placebo, treating insulin resistance</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide</title>
            <description>Randomized to leuprolide plus metformin placebo, pharmacologic lowering of testosterone</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo metformin plus placebo leuprolide</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Free Testosterone (T)</title>
          <description>Percent change in free T by equilibrium dialysis between baseline and 12 weeks</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="22.8"/>
                    <measurement group_id="O2" value="-35.8" spread="31.8"/>
                    <measurement group_id="O3" value="12.1" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Insulin Sensitivity</title>
        <description>Change in insulin sensitivity (mg/kg/min) calculated from hyperinsulinemic euglycemic clamp</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Randomized to metformin plus leuprolide placebo, treating insulin resistance</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide</title>
            <description>Randomized to leuprolide plus metformin placebo, pharmacologic lowering of testosterone</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo metformin plus placebo leuprolide</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Sensitivity</title>
          <description>Change in insulin sensitivity (mg/kg/min) calculated from hyperinsulinemic euglycemic clamp</description>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.80"/>
                    <measurement group_id="O2" value="0.04" spread="0.81"/>
                    <measurement group_id="O3" value="-0.08" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Luteinizing Hormone (LH) From Baseline</title>
        <time_frame>baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Randomized to metformin plus leuprolide placebo, treating insulin resistance</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide</title>
            <description>Randomized to leuprolide plus metformin placebo, pharmacologic lowering of testosterone</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo metformin plus placebo leuprolide</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Luteinizing Hormone (LH) From Baseline</title>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="-5.6" upper_limit="9.8"/>
                    <measurement group_id="O2" value="-96.5" lower_limit="-210.2" upper_limit="-46.3"/>
                    <measurement group_id="O3" value="-1.2" lower_limit="-3.9" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Homeostasis Model Assessment Index of Insulin Resistance (HOMA-IR)</title>
        <description>Insulin resistance calculated from homeostasis model assessment of insulin resistance (HOMA-IR) equation: fasting insulin x fasting glucose / 405. Higher values indicate more insulin resistance.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Randomized to metformin plus leuprolide placebo, treating insulin resistance</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide</title>
            <description>Randomized to leuprolide plus metformin placebo, pharmacologic lowering of testosterone</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo metformin plus placebo leuprolide</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Homeostasis Model Assessment Index of Insulin Resistance (HOMA-IR)</title>
          <description>Insulin resistance calculated from homeostasis model assessment of insulin resistance (HOMA-IR) equation: fasting insulin x fasting glucose / 405. Higher values indicate more insulin resistance.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.0" spread="24.39"/>
                    <measurement group_id="O2" value="-8.18" spread="35.3"/>
                    <measurement group_id="O3" value="4.67" spread="38.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Low Density Lipoprotein (LDL)</title>
        <time_frame>baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Randomized to metformin plus leuprolide placebo, treating insulin resistance</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide</title>
            <description>Randomized to leuprolide plus metformin placebo, pharmacologic lowering of testosterone</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo metformin plus placebo leuprolide</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low Density Lipoprotein (LDL)</title>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="22.2"/>
                    <measurement group_id="O2" value="5.3" spread="19.3"/>
                    <measurement group_id="O3" value="25.3" spread="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Systolic Blood Pressure</title>
        <time_frame>baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Randomized to metformin plus leuprolide placebo, treating insulin resistance</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide</title>
            <description>Randomized to leuprolide plus metformin placebo, pharmacologic lowering of testosterone</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo metformin plus placebo leuprolide</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Systolic Blood Pressure</title>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="8.6"/>
                    <measurement group_id="O2" value="4.0" spread="13.6"/>
                    <measurement group_id="O3" value="-0.3" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free T and IR in Women in Whom Metabolic Syndrome is Present vs. Absent</title>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Data were not collected and the outcome will never be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Randomized to metformin plus leuprolide placebo, treating insulin resistance</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide</title>
            <description>Randomized to leuprolide plus metformin placebo, pharmacologic lowering of testosterone</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo metformin plus placebo leuprolide</description>
          </group>
        </group_list>
        <measure>
          <title>Free T and IR in Women in Whom Metabolic Syndrome is Present vs. Absent</title>
          <population>Data were not collected and the outcome will never be analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dehydroepiandrosterone Sulfate (DHEA-S)</title>
        <time_frame>baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Randomized to metformin plus leuprolide placebo, treating insulin resistance</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide</title>
            <description>Randomized to leuprolide plus metformin placebo, pharmacologic lowering of testosterone</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo metformin plus placebo leuprolide</description>
          </group>
        </group_list>
        <measure>
          <title>Dehydroepiandrosterone Sulfate (DHEA-S)</title>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="-10.5" upper_limit="18.4"/>
                    <measurement group_id="O2" value="0.9" lower_limit="-15.5" upper_limit="21.1"/>
                    <measurement group_id="O3" value="-2.9" lower_limit="-17.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index (BMI)</title>
        <time_frame>baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Randomized to metformin plus leuprolide placebo, treating insulin resistance</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide</title>
            <description>Randomized to leuprolide plus metformin placebo, pharmacologic lowering of testosterone</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo metformin plus placebo leuprolide</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="3.2"/>
                    <measurement group_id="O2" value="0.1" spread="1.5"/>
                    <measurement group_id="O3" value="0.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>metformin plus leuprolide placebo (LP) injection</description>
        </group>
        <group group_id="E2">
          <title>Leuprolide</title>
          <description>leuprolide plus metformin placebo (MP) pill</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>MP placebo pill plus LP placebo injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne R. Cappola, M.D., ScM</name_or_title>
      <organization>University of Pennsylvania, School of Medicine</organization>
      <phone>(215) 573-5359</phone>
      <email>ACappola@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

